All In Biotech

Drug Trial Radar · NCT03840616

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

Phase 3, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules vs Fluconazole and Placebo in Treatment of Acute Vulvovaginal Candidiasis in Subjects With Recurrent Vulvovaginal Candidiasis

Last checked: Nov 20, 2026Latest source record: Feb 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

219

Actual

Start

Mar 13, 2019

Primary completion

Dec 2, 2020

Study completion Dec 2, 2020

Sponsor

Lead sponsor
Mycovia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute vulvovaginal candidiasis (VVC) in the past 12 months. Several properties of oteseconazole (VT-1161) suggest it might be a safer and more effective treatment of RVVC than other oral antifungal medications. This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment of acute VVC episodes in patients with RVVC and consists of 2 parts. The first part of the study is a 2-week induction phase for the treatment of the patient's current VVC episode when the patient will take either fluconazole or oteseconazole (VT-1161) according to a random assignment. The second part consists of an 11-week maintenance phase, when the patient will take either oteseconazole (VT-1161) or a placebo according to the random assignment from the first part of the study, and then a 37-week follow-up period.

Conditions

  • Recurrent Vulvovaginal Candidiasis

Interventions

  • Oteseconazole (VT-1161) 150mg capsuleDrug

    600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.

  • Fluconazole 150mg capsuleDrug

    150mg administered every 72 hours in 3 sequential doses starting on Day 1.

  • PlaceboDrug

    Administered once weekly starting on Day 14.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) PopulationTime frame: 48 Weeks

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • 34

    Tucson, Arizona

  • 39

    Encino, California

  • 25

    Los Angeles, California

  • 22

    Englewood, Colorado

  • 49

    Boca Raton, Florida

  • 14

    Gainesville, Florida

  • 13

    Leesburg, Florida

  • 33

    Loxahatchee Groves, Florida

  • 36

    Miami, Florida

  • 17

    Savannah, Georgia

  • 27

    Idaho Falls, Idaho

  • 10

    Nampa, Idaho

  • 62

    Chicago, Illinois

  • 41

    Fort Wayne, Indiana

  • 30

    Marrero, Louisiana

  • 50

    Dearborn Heights, Michigan

  • 29

    Saginaw, Michigan

  • 55

    Traverse City, Michigan

  • 32

    Troy, Michigan

  • 26

    Kansas City, Missouri

  • 42

    New Brunswick, New Jersey

  • 47

    Ocean City, New Jersey

  • 37

    Charlotte, North Carolina

  • 38

    Fayetteville, North Carolina

  • 15

    Columbus, Ohio

  • 18

    Bluffton, South Carolina

  • 48

    Myrtle Beach, South Carolina

  • 20

    Bristol, Tennessee

  • 21

    Murfreesboro, Tennessee

  • 24

    Austin, Texas

  • 23

    Fort Worth, Texas

  • 63

    Katy, Texas

  • 58

    League City, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.